Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Quintiles: 4th Qtr Sales US$404 Million
February 25, 2002
- ICH ETWG Compiles Q&A for Implementation of CTD
February 25, 2002
- Sanofi-Synthelabo, Organon Launch Arixtra in US
February 25, 2002
- REGULATORY NEWS IN BRIEF
February 25, 2002
- BULLETIN
February 25, 2002
- Very Confident of Our Future in Japan: Mr Payne of Pharmacia
February 25, 2002
- Hodanren Sets Up Cooperative Generics Purchasing System
February 25, 2002
- Sales Increase by 14.1% to \75 Bil.: Nippon Roche
February 25, 2002
- Novartis: Sales Up 14% to CHF32 Bil.
February 25, 2002
- 50,000 Long-admitted Elderly May Be Transferred to Nursing Care Insurance
February 25, 2002
- Tanabe Licenses Tanatril to aaiPharma
February 25, 2002
- GPs Are Reluctant to Conduct H. pylori Eradication Therapy: JGCA Meeting
February 25, 2002
- Marketing Suspension of Berotec Aerosol Requested by Medwatcher Japan
February 18, 2002
- JMA Committee Opposed to Increases in Copayment
February 18, 2002
- New System to Widen Gaps between Generic Houses: EMA President
February 18, 2002
- Top Priority Should Be Put on Pharmaceutical Education Reform: JSHP President
February 18, 2002
- 4 Companies Form Group to Promote Generics
February 18, 2002
- Terumo: Consolidated 3rd Qtr Sales Total \49,772 Mil.
February 18, 2002
- WEBSITE NEWS
February 18, 2002
- J-Phone Develops New System Directly Transferring Images to Mobile Phone
February 18, 2002
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…